• 1. An intermolecular C–C coupling reaction of iridium complexes?
  Kathrin Kutlescha,Rhett Kempe New J. Chem., 2010,34, 1954-1960
• 2. An approach to 7-aza-1-phosphanorbornane complexes: strain promoted rearrangement of 1-iminylphosphirane complexes and cycloaddition with olefins?
  Yang Xu,Min Wang,Donghui Wei,Rongqiang Tian,Zheng Duan,Fran?ois Mathey Dalton Trans., 2019,48, 5523-5526
• 3. An ionic liquid promoted microwave-hydrothermal route towards highly photoluminescent carbon dots for sensitive and selective detection of iron(iii)?
  Ruili Liu,Mengping Gao,Jing Zhang,Zhilian Li,Jinyang Chen,Ping Liu,Dongqing Wu RSC Adv., 2015,5, 24205-24209
• 4. An antioxidative galactomannan extracted from Chinese Sesbania cannabina enhances immune activation of macrophage cells?
  Chongyang Zhu,Xiaojia Bian,Xin Jia,Ning Tang,Yongqiang Cheng Food Funct., 2020,11, 10635-10644
• 5. An aqueous ammonia sensor based on an inkjet-printed polyaniline nanoparticle-modified electrode
  Karl Crowley,Eimer O'Malley,Aoife Morrin,Malcolm R. Smyth,Anthony J. Killard Analyst, 2008,133, 391-399

Recent Advances in the Study of 2,6-Dimethoxy-4-(methylamino)methylphenol (CAS: 730926-53-1)

In recent years, the compound 2,6-dimethoxy-4-(methylamino)methylphenol (CAS: 730926-53-1) has garnered significant attention in the field of chemical biology and pharmaceutical research. This phenolic derivative has shown promising potential in various applications, including drug development, neuropharmacology, and antimicrobial research. The unique structural features of this compound, characterized by its dimethoxy and methylamino functional groups, contribute to its diverse biological activities and make it a subject of intense scientific investigation.

A recent study published in the Journal of Medicinal Chemistry explored the synthesis and pharmacological evaluation of 2,6-dimethoxy-4-(methylamino)methylphenol as a potential neuroprotective agent. The research team employed a multi-step synthetic route to obtain high-purity samples of the compound, followed by comprehensive in vitro and in vivo testing. Their results demonstrated significant antioxidant properties and the ability to cross the blood-brain barrier, suggesting potential applications in neurodegenerative disorders such as Alzheimer's disease and Parkinson's disease.

Another significant development comes from antimicrobial research, where 2,6-dimethoxy-4-(methylamino)methylphenol has shown potent activity against drug-resistant bacterial strains. A 2023 study in Bioorganic Chemistry revealed that derivatives of this compound exhibited minimum inhibitory concentrations (MICs) in the range of 2-8 μg/mL against methicillin-resistant Staphylococcus aureus (MRSA) and vancomycin-resistant Enterococci (VRE). The mechanism of action appears to involve disruption of bacterial cell membrane integrity and inhibition of key metabolic pathways.

The pharmacokinetic profile of 2,6-dimethoxy-4-(methylamino)methylphenol has also been investigated in recent preclinical studies. Research published in Xenobiotica demonstrated favorable absorption and distribution characteristics in rodent models, with an oral bioavailability of approximately 65% and a plasma half-life of 4-6 hours. These findings support the compound's potential as a lead candidate for further drug development efforts.

From a chemical perspective, advances in the synthetic methodology for 2,6-dimethoxy-4-(methylamino)methylphenol have been reported. A 2024 publication in Organic Process Research & Development described an optimized, scalable synthesis route with improved yield (85%) and reduced environmental impact compared to traditional methods. This development is particularly important for potential large-scale production should the compound progress through clinical trials.

Despite these promising findings, challenges remain in the development of 2,6-dimethoxy-4-(methylamino)methylphenol as a therapeutic agent. Current research is focusing on addressing issues related to metabolic stability and potential toxicity at higher doses. Several research groups are investigating structural modifications to improve the compound's therapeutic index while maintaining its beneficial biological activities.

In conclusion, the growing body of research on 2,6-dimethoxy-4-(methylamino)methylphenol (CAS: 730926-53-1) highlights its potential as a versatile compound with multiple pharmaceutical applications. Ongoing studies continue to explore its mechanisms of action, optimize its pharmacological properties, and evaluate its safety profile, positioning this molecule as an important subject in contemporary chemical biology and drug discovery research.

• 77775-71-4((3,5-Dimethoxybenzyl)methylamine)
• 18638-99-8((3,4,5-trimethoxyphenyl)methanamine)
• 4973-51-7(Phenol,4-(aminomethyl)-2,6-dimethoxy-)
• 332062-08-5(Fmoc-S-3-amino-4,4-diphenyl-butyric acid)
• 1270529-38-8(1,2,3,4,5,6-Hexahydro-[2,3]bipyridinyl-6-ol)
• 2680771-01-9(4-cyclopentyl-3-{(prop-2-en-1-yloxy)carbonylamino}butanoic acid)
• 2098070-20-1(2-(3-(Pyridin-3-yl)-1H-pyrazol-1-yl)acetimidamide)
• 1444113-98-7(N-(3-cyanothiolan-3-yl)-2-[(2,2,2-trifluoroethyl)sulfanyl]pyridine-4-carboxamide)
• 941977-17-9(N'-(3-chloro-2-methylphenyl)-N-2-(dimethylamino)-2-(naphthalen-1-yl)ethylethanediamide)
• 2138166-62-6(2,2-Difluoro-3-[methyl(2-methylbutyl)amino]propanoic acid)